Tag: cardiac biomarkers market growth

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Cardiac Biomarkers Market Size Changed, over the years?

In recent years, the size of the cardiac biomarkers market has seen a swift expansion. It is predicted to rise from $18.99 billion in 2024 to $21.32 billion in 2025, with a compound annual growth rate (CAGR) of 12.3%. Factors such as elevated healthcare expenditure, FDA approvals and regulatory backing, an aging populace, awareness campaigns, high sensitivity troponin tests, and a surge in cardiovascular diseases are responsible for the growth experienced in the historic period.

How Much Will the Cardiac Biomarkers Market Be Worth in 2029?

The market size of cardiac biomarkers is forecasted to experience significant growth in the upcoming years, predicted to reach “$36.51 billion by 2029 with a compound annual growth rate (CAGR) of 14.4%. Reasons for this growth during the forecast period include the increasing prevalence of chronic diseases, a greater focus on early disease identification, an aging population, developing emerging markets, and a concentration on biomarker panels. Key trends predicted during this period encompass patient-focused healthcare models, the use of AI and machine learning, integration of digital health, technological advancements in biomarker discovery, multi-marker panels, and the use of liquid biopsy in cardiovascular medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

Which is the Largest Company in the Cardiac Biomarkers Market?

Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

What Are the Main Market Drivers in the Cardiac Biomarkers Industry?

The escalating incidence of cardiovascular ailments is set to fuel the expansion of the cardiac biomarker market. Such ailments, which impair the heart and blood vessels, encompass coronary artery disease, heart failure, and stroke among others. Cardiac biomarkers, which are provoked into the bloodstream by certain cardiovascular diseases such as myocardial infarction (heart attack), heart failure, and arrhythmias, can be quantified via laboratory tests. These levels can yield significant diagnostic and prognostic details. For example, data released by the British Heart Foundation in September 2024 revealed that around 7.6 million people in the UK, including approximately 4 million men and 3.6 million women, suffer from heart and circulatory diseases. These disorders play a role in about 27% of UK deaths, resulting in over 170,000 deaths each year or roughly 480 deaths daily, which amounts to a death every three minutes. Consequently, the increasing incidence of cardiovascular diseases is accelerating the expansion of the cardiac biomarker market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10234&type=smp

How Is the Cardiac Biomarkers Market Segments Structured?

The cardiac biomarkers market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types

2) By Location Of Testing: Point Of Care Testing, Laboratory Testing

3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications

4) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels

2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels

3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels

4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels

5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels

6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

What Strategic Trends Are Transforming the Cardiac Biomarkers Market?

The cardiac biomarker market is witnessing an uptick in cutting-edge technological practices, a trend predominantly triggered by corporations striving to maintain their influence in the sector. As part of this, the medical devices firm based in China, Mindray, unveiled novel high-sensitivity cardiac biomarkers troponin I (hs-cTnI) and NT-proBNP in October 2023, aiming to boost the diagnosis and control of cardiovascular diseases (CVDs). The hs-cTnI biomarker is crucial for detecting myocardial injury, thanks to its remarkable detection capabilities and minimal imprecision, making it ideal for early screening and risk evaluation in circumstances such as Acute Coronary Syndrome (ACS). Conversely, NT-proBNP stands as a reputable marker for heart failure, aiding its identification and management, while exhibiting outstanding precision and limited disruption from commonly prescribed heart drugs. Collectively, these biomarkers significantly enhance clinical decisions related to urgent cardiovascular treatments.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

Which Global Regions Offer the Highest Growth in the Cardiac Biomarkers Market?

North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234

This Report Delivers Insight On:

1. How big is the cardiac biomarkers market, and how is it changing globally?

2. Who are the major companies in the cardiac biomarkers market, and how are they performing?

3. What are the key opportunities and risks in the cardiac biomarkers market right now?

4. Which products or customer segments are growing the most in the cardiac biomarkers market?

5. What factors are helping or slowing down the growth of the cardiac biomarkers market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cardiac biomarkers industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Anticipated CAGR of the Cardiac Biomarkers Market, and What Factors Will Drive It?

In recent years, the cardiac biomarkers market has seen rapid expansion. Its forecasted growth projects an increase from $18.99 billion in 2024 to $21.32 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.3%. Factors contributing to this growth during the historic period include elevated healthcare spending, FDA authorizations as well as regulatory backing, an aging demographic, educational initiatives, widespread use of highly sensitive troponin tests, and a rise in cardiovascular diseases.

The market for cardiac biomarkers is predicted to experience swift expansion in the coming years. With a compound annual growth rate (CAGR) of 14.4%, the market is projected to reach $36.51 billion in 2029. The expected growth during this period can be linked to the increasing prevalence of chronic illnesses, the heightened emphasis on early diagnosis of diseases, the growing size of the elderly population, advancements in emerging markets, and the focus on biomarker panels. Notable trends expected during this forecast period include the adoption of patient-focused healthcare models, the application of AI and machine learning, the integration of digital health, technological advancements in biomarker discovery, multi-marker panels, and the use of liquid biopsy in cardiovascular medicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Cardiac Biomarkers Market?

The increasing incidence of cardiovascular diseases is anticipated to drive the expansion of the cardiac biomarker market. Cardiovascular diseases, which encompass conditions like coronary artery disease, heart failure, and stroke, impact the heart and the blood vessels. Cardiac biomarkers, substances that are secreted into the bloodstream due to specific cardiovascular ailments including myocardial infarction (heart attack), heart failure, and arrhythmias, can be quantified using laboratory tests, offering critical diagnostic and prognostic data. For example, in September 2024, information released by the British Heart Foundation, a UK-based cardiovascular research charity, revealed that in the UK, about 7.6 million individuals suffer from heart and circulatory disorders, including nearly 4 million men and 3.6 million women. These diseases account for approximately 27% of UK’s total fatalities, equivalent to over 170,000 deaths per year, or about 480 deaths daily, resulting in one death every three minutes. As a result, the growing incidence of these cardiovascular ailments is fostering the expansion of the cardiac biomarker market.

Which Primary Segments of the Cardiac Biomarkers Market Are Driving Growth and Industry Transformations?

The cardiac biomarkers market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types

2) By Location Of Testing: Point Of Care Testing, Laboratory Testing

3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications

4) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels

2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels

3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels

4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels

5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels

6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=10234&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Cardiac Biomarkers Market?# Market?

North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Most Significant Market Trends in the Cardiac Biomarkers Market?

The rising trends in the cardiac biomarker market are largely influenced by technological innovations. In an effort to maintain their market positions, businesses in this sector are leveraging new technologies. As an example, Mindray, a medical devices company headquartered in China, launched innovative high-sensitivity cardiac biomarkers – troponin I (hs-cTnI) and NT-proBNP – in October 2023. These were specifically designed to boost the identification and treatment processes for cardiovascular diseases (CVDs). The hs-cTnI biomarker is particularly significant for diagnosing myocardial injury due to its high detection rate and precise results, making it the perfect tool for early screenings and risk evaluations especially in cases such as Acute Coronary Syndrome (ACS). Conversely, NT-proBNP is a trusted biomarker used for diagnosing heart failure, enhancing its detection and management while consistently delivering precise results and showing minimal interaction with commonly prescribed heart medications. These biomarkers as a collective significantly transform clinical decision-making in emergency cardiovascular care.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

What Parameters Are Used to Define the Cardiac Biomarkers Market?

Cardiac biomarkers are chemicals released by heart into the blood when it is injured or under stress. It used for the detection and measurement of various cardiac vascular diseases.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Cardiac Biomarkers Market?

The escalation in the incidence of cardiovascular diseases is predicted to boost the progression of the cardiac biomarker market. Cardiovascular diseases, which include conditions like coronary artery disease, heart failure, and stroke, impact the heart and blood vessels. In the event of certain cardiac issues such as myocardial infarction (heart attack), heart failure, and arrhythmias, cardiac biomarkers are released into the bloodstream. These biomarkers can be quantified by laboratory tests and offer valuable diagnostic and prognostic data. For example, as per the British Heart Foundation’s data published in September 2024, nearly 7.6 million people in the UK, approximately 4 million men and 3.6 million women, suffer from heart and circulatory diseases. These diseases account for a staggering 27% of all deaths in the UK, resulting in over 170,000 deaths a year, or nearly 480 deaths a day, signifying one death every three minutes. Hence, the increasing prevalence of cardiovascular diseases is contributing substantially to the expansion of the cardiac biomarker market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

#What is the Anticipated CAGR of theCardiac Biomarkers Market, and What Factors Will Drive It?

In the recent past, the cardiac biomarkers market has experienced a swift expansion. With a projected Compound Annual Growth Rate (CAGR) of 12.3%, the market is expected to rise from $18.99 billion in 2024 to $21.32 billion in 2025. The unprecedented growth during the historic period can be linked to factors such as heightened healthcare expenditures, FDA authorizations and regulatory backing, an aging populace, awareness campaigns, the prevalence of high sensitivity troponin tests, and a rise in cardiovascular ailment cases.

The market size for cardiac biomarkers is predicted to experience significant expansion in the coming years, reaching $36.51 billion in 2029 with a CAGR of 14.4%. The expected proliferation during the predicted period is due to the increasing incidence of chronic illnesses, a heightened focus on early disease identification, the growth of elderly populations, developing markets, and concentration on biomarker panels. The forecast period also suggests trends such as healthcare models centered around patients, application of AI and machine learning, incorporation of digital health, tech advancements in biomarker identification, panels of multiple markers, and use of liquid biopsy in cardiovascular medicine.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234

What Are the Most Significant Market Trends Transforming theCardiac Biomarkers Market?

The incorporation of cutting-edge technology is a predominant trend emerging in the cardiac biomarker market. Firms in this market are employing new technological advancements to maintain their market position. For example, Mindray, a medical device firm based in China, introduced new highly sensitive cardiac biomarkers troponin I (hs-cTnI) and NT-proBNP in October 2023, with the aim to enhance the management and diagnosis of cardiovascular diseases (CVDs). The hs-cTnI biomarker is essential in detecting myocardial damage with highly impressive rates of detection and minimal imprecision, making it of much worth for early screening and risk assessment in situations such as Acute Coronary Syndrome (ACS). NT-proBNP, on the other hand, is a well-recognized marker for heart failure which helps in its detection and management. It is notable for its high precision and lacks interference from widely used cardiac medications. Collectively, these biomarkers significantly contribute to improved clinical decisions in urgent cardiovascular care scenarios.

What Are the Top Market Players Propelling the Growth of theCardiac Biomarkers Industry?

Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

Which Primary Segments of the Cardiac Biomarkers Market Are Driving Growth and Industry Transformations?

The cardiac biomarkers market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types

2) By Location Of Testing: Point Of Care Testing, Laboratory Testing

3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications

4) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels

2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels

3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels

4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels

5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels

6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=10234&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Cardiac Biomarkers Market?# Market?

North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Cardiac Biomarkers Maret 2025, By The Business Research Company:

Cardiac Assist Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

Cardiovascular Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiac Valve Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-valve-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Cardiac Biomarkers Market?

The escalation in the incidence of cardiovascular diseases is predicted to boost the progression of the cardiac biomarker market. Cardiovascular diseases, which include conditions like coronary artery disease, heart failure, and stroke, impact the heart and blood vessels. In the event of certain cardiac issues such as myocardial infarction (heart attack), heart failure, and arrhythmias, cardiac biomarkers are released into the bloodstream. These biomarkers can be quantified by laboratory tests and offer valuable diagnostic and prognostic data. For example, as per the British Heart Foundation’s data published in September 2024, nearly 7.6 million people in the UK, approximately 4 million men and 3.6 million women, suffer from heart and circulatory diseases. These diseases account for a staggering 27% of all deaths in the UK, resulting in over 170,000 deaths a year, or nearly 480 deaths a day, signifying one death every three minutes. Hence, the increasing prevalence of cardiovascular diseases is contributing substantially to the expansion of the cardiac biomarker market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

#What is the Anticipated CAGR of theCardiac Biomarkers Market, and What Factors Will Drive It?

In the recent past, the cardiac biomarkers market has experienced a swift expansion. With a projected Compound Annual Growth Rate (CAGR) of 12.3%, the market is expected to rise from $18.99 billion in 2024 to $21.32 billion in 2025. The unprecedented growth during the historic period can be linked to factors such as heightened healthcare expenditures, FDA authorizations and regulatory backing, an aging populace, awareness campaigns, the prevalence of high sensitivity troponin tests, and a rise in cardiovascular ailment cases.

The market size for cardiac biomarkers is predicted to experience significant expansion in the coming years, reaching $36.51 billion in 2029 with a CAGR of 14.4%. The expected proliferation during the predicted period is due to the increasing incidence of chronic illnesses, a heightened focus on early disease identification, the growth of elderly populations, developing markets, and concentration on biomarker panels. The forecast period also suggests trends such as healthcare models centered around patients, application of AI and machine learning, incorporation of digital health, tech advancements in biomarker identification, panels of multiple markers, and use of liquid biopsy in cardiovascular medicine.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234

What Are the Most Significant Market Trends Transforming theCardiac Biomarkers Market?

The incorporation of cutting-edge technology is a predominant trend emerging in the cardiac biomarker market. Firms in this market are employing new technological advancements to maintain their market position. For example, Mindray, a medical device firm based in China, introduced new highly sensitive cardiac biomarkers troponin I (hs-cTnI) and NT-proBNP in October 2023, with the aim to enhance the management and diagnosis of cardiovascular diseases (CVDs). The hs-cTnI biomarker is essential in detecting myocardial damage with highly impressive rates of detection and minimal imprecision, making it of much worth for early screening and risk assessment in situations such as Acute Coronary Syndrome (ACS). NT-proBNP, on the other hand, is a well-recognized marker for heart failure which helps in its detection and management. It is notable for its high precision and lacks interference from widely used cardiac medications. Collectively, these biomarkers significantly contribute to improved clinical decisions in urgent cardiovascular care scenarios.

What Are the Top Market Players Propelling the Growth of theCardiac Biomarkers Industry?

Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

Which Primary Segments of the Cardiac Biomarkers Market Are Driving Growth and Industry Transformations?

The cardiac biomarkers market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types

2) By Location Of Testing: Point Of Care Testing, Laboratory Testing

3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications

4) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels

2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels

3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels

4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels

5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels

6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=10234&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Cardiac Biomarkers Market?# Market?

North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Cardiac Biomarkers Maret 2025, By The Business Research Company:

Cardiac Assist Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

Cardiovascular Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiac Valve Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-valve-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the cardiac biomarkers market?

In the past few years, the market size of cardiac biomarkers has expanded exponentially. The industry, which was valued at $18.99 billion in 2024, is predicted to reach a valuation of $21.32 billion in 2025, growing at a compound annual growth rate (CAGR) of 12.3%. Several factors have spurred this growth during the historical period, including escalated healthcare expenditures, FDA endorsements, regulatory backing, the aging demographic, consciousness campaigns, high-sensitivity troponin exams, and the rise in cardiovascular ailments.

What will be the cardiac biomarkers market size in the future?

In the coming years, the cardiac biomarkers market is predicted to experience a surge in size. The market is projected to reach “$36.51 billion by 2029, with a compound annual growth rate (CAGR) of 14.4%. This growth in the forecasted timeframe is due to an increasing prevalence of chronic illnesses, heightened emphasis on disease detection in its early stages, a growing elderly population, the development of emerging markets, and a focus on biomarker panels. Key trends for this forecast period include healthcare models centered on the patient, the application of artificial intelligence and machine learning, the integration of digital health, novel technology in biomarker discovery, multi-marker panels, and the use of liquid biopsy in cardiovascular medicine.

Get your cardiac biomarkers market report here!

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

What main drivers are fueling expansion in the cardiac biomarkers market?

The burgeoning incidence of cardiovascular diseases is likely to boost the expansion of the cardiac biomarker market. Cardiovascular diseases, which impact the heart and blood vessels, encapsulate conditions such as coronary artery disease, heart failure, and stroke. These conditions result in the release of cardiac biomarkers into the bloodstream, which can be detected through lab tests. The levels of these biomarkers offer critical diagnostic and predictive data. For instance, the British Heart Foundation released figures in September 2024, revealing that roughly 7.6 million people, 4 million males and 3.6 million females, live with heart and circulatory issues in the UK. These diseases account for almost 27% of all fatalities in the country, leading to over 170,000 deaths per year, or nearly 480 deaths per day; this translates to a death every three minutes. This escalating incidence of cardiovascular diseases is fueling the expansion of the cardiac biomarker market.

What key areas define the segmentation of the global cardiac biomarkers market?

The cardiac biomarkers market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types

2) By Location Of Testing: Point Of Care Testing, Laboratory Testing

3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications

4) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels

2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels

3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels

4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels

5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels

6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

Who are the dominant players expanding their reach in the cardiac biomarkers market?

Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

How are evolving market trends shaping cardiac biomarkers Strategies?

One of the main developments in the cardiac biomarker market is the increasing prevalence of technological advancements. In order to maintain their market standing, organizations in this space are embracing innovative technologies. For instance, in October 2023, Mindray, a medical devices firm based in China, unveiled new high-sensitivity cardiac biomarkers, troponin I (hs-cTnI) and NT-proBNP to help enhance the detection and management of cardiovascular diseases (CVDs). The hs-cTnI biomarker is especially crucial in determining myocardial injury, known for its impressive diagnosis rate and low flaws, making it essential for early screening and risk evaluation in situations like Acute Coronary Syndrome (ACS). Conversely, NT-proBNP is a recognized marker for heart failure, aiding its detection and management by demonstrating high accuracy and little disturbance from commonly used cardiac drugs. These biomarkers collectively enhance medical decision-making in urgent heart care circumstances.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234

Which regions are emerging as leaders in the cardiac biomarkers market?

North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Cardiac Assist Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

Cardiovascular Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiac Valve Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-valve-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR Will the Cardiac Biomarkers Market Achieve During 2025–2034, and What Does It Indicate?

The market for cardiac biomarkers has seen considerable growth in the past few years. The market, which was valued at $18.99 billion in 2024, is projected to reach $21.32 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.3%. The historic surge in growth can be related to factors such as increased spending in healthcare, endorsement and regulatory aid from the FDA, an aging demographic, increased awareness initiatives, the advent of highly sensitive troponin tests, and a rise in cardiovascular conditions.

In the coming years, the cardiac biomarkers market is projected to experience substantial growth, estimated to reach a valuation of “$36.51 billion” by 2029, growing at a compound annual growth rate (CAGR) of 14.4%. This growth during the forecast period could be attributed to various factors including, increasing prevalence of chronic diseases, a heightened focus on early diagnosis of diseases, growth in the aged population, advancement in emerging markets, and a growing interest in biomarker panels. Forecast period trends comprise patient-centric healthcare approaches, application of AI and machine learning in healthcare, the integration of digital health, technological breakthroughs in discovering biomarkers, the use of multi-marker panels, and the implementation of liquid biopsy in cardiovascular medicine.

What Are the Primary Drivers Supporting the Growth of the cardiac biomarkers Market?

The cardiac biomarker market is anticipated to experience significant growth due to the increasing occurrence of cardiovascular disorders. Diseases impacting the heart and blood vessels – like coronary artery disease, heart failure, and stroke – fall under the umbrella of cardiovascular disorders. When the body encounters conditions such as myocardial infarction (heart attack), heart failure, and arrhythmias, cardiac biomarkers are dispatched to the bloodstream. Laboratory tests can then measure and provide crucial diagnostic and prognostic data regarding these biomarkers. A case in point, in September 2024, the UK-based cardiovascular research charity – the British Heart Foundation – disclosed that, in the UK alone, around 7.6 million people are grappling with heart and circulatory diseases, including an estimated 4 million men and 3.6 million women. These diseases account for nearly a 27-percent death rate in the UK, which translates to more than 170,000 deaths per year, or approximately 480 deaths daily; essentially, one death every three minutes. Given these circumstances, the cardiac biomarker market is being propelled by the growing prevalence of cardiovascular disorders.

Explore Comprehensive Insights Into The Global Cardiac Biomarkers Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

Who Are the Key Firms Paving the Way for Growth in the Cardiac Biomarkers Market?

Major companies operating in the cardiac biomarkers market include:

• bioMerieux Inc._x000D_

• Bio-Rad Laboratories_x000D_

• F. Hoffmann-La Roche AG_x000D_

• Siemens AG_x000D_

• Thermo Fisher Scientific Inc._x000D_

What Are the Most Influential Trends Currently Shaping the Cardiac Biomarkers Market?

Technological innovation stands out as one major trend becoming increasingly popular within the cardiac biomarker market. Companies involved in this market are leveraging novel technologies to maintain their competitiveness. For instance, China’s Mindray, a medical device company, introduced new high-sensitivity cardiac biomarkers troponin I (hs-cTnI) and NT-proBNP in October 2023 to improve cardiovascular disease diagnosis and management. The hs-cTnI biomarker is critical in pinpointing myocardial injury, demonstrating remarkable detection capabilities and negligible imprecision, hence its value in early screening and risk evaluation in instances such as Acute Coronary Syndrome (ACS). On the other hand, NT-proBNP has cemented its place as a reliable indicator for heart failure, assisting in its detection and management—particularly due to its high accuracy and minimal interference with commonly administered heart medication. Collectively, these biomarkers greatly enhance clinical decision-making for emergency cardiovascular situations.

Secure Your Global Cardiac Biomarkers Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

Which Key Segments of the Cardiac Biomarkers Market Are Poised for Growth and Innovation?

The cardiac biomarkers market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types

2) By Location Of Testing: Point Of Care Testing, Laboratory Testing

3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications

4) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels

2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels

3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels

4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels

5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels

6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

Which Regions Are Essential for the Growth of the Cardiac Biomarkers Market?

North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Definition of the Cardiac Biomarkers Market Impacting Future Growth?

Cardiac biomarkers are chemicals released by heart into the blood when it is injured or under stress. It used for the detection and measurement of various cardiac vascular diseases.

Browse Through More Similar Reports By The Business Research Company:

Cardiac Assist Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

Cardiovascular Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiac Valve Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-valve-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: